Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272138 | 0.86 | HSD11B1 (0.41) | HSD11B1PIK3CGOPRM1MAPK1 | |
| SCHEMBL2024711 | 0.86 | HSD11B1 (0.41) | HSD11B1PIK3CGOPRM1MAPK1 | |
| SCHEMBL2024943 | 0.86 | HSD11B1 (0.44) | HSD11B1PIK3CGOPRM1THRBNPBWR1 | |
| SCHEMBL2027111 | 0.85 | HSD11B1 (0.44) | HSD11B1PIK3CGMDM2OPRM1THRB | |
| SCHEMBL2024712 | 0.83 | PIK3CG (0.43) | HSD11B1PIK3CGMAPK1 | |
| SCHEMBL2024709 | 0.83 | PIK3CG (0.43) | HSD11B1PIK3CGMAPK1 | |
| SCHEMBL12442511 | 0.81 | PIK3CG (0.40) | HSD11B1PIK3CGMAPK1 | |
| SCHEMBL8239554 | 0.76 | PIK3CG (0.39) | HSD11B1PIK3CGOPRM1MAPK1 | |
| SCHEMBL8272139 | 0.76 | ACHE (0.39) | HSD11B1MDM2OPRM1MAPK1 | |
| SCHEMBL1001744 | 0.76 | ACHE (0.39) | HSD11B1MDM2OPRM1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | HSD11B1 492/4885PIK3CG 1735/4885MDM2 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.